Clinical Pharmacokinetic Studies of Enzalutamide

BACKGROUND AND OBJECTIVES: Oral enzalutamide (160 mg once daily) is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This article describes the pharmacokinetics of enzalutamide and its active metabolite N-desmethyl enzalutamide. METHODS: Results are reported fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibbons, Jacqueline A., Ouatas, Taoufik, Krauwinkel, Walter, Ohtsu, Yoshiaki, van der Walt, Jan-Stefan, Beddo, Vanessa, de Vries, Michiel, Mordenti, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580721/
https://www.ncbi.nlm.nih.gov/pubmed/25917876
http://dx.doi.org/10.1007/s40262-015-0271-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580721/
https://www.ncbi.nlm.nih.gov/pubmed/25917876
http://dx.doi.org/10.1007/s40262-015-0271-5

Ejemplares similares